343 related articles for article (PubMed ID: 22842629)
1. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management.
Adhami VM; Syed DN; Khan N; Mukhtar H
Biochem Pharmacol; 2012 Nov; 84(10):1277-81. PubMed ID: 22842629
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Khan N; Afaq F; Khusro FH; Mustafa Adhami V; Suh Y; Mukhtar H
Int J Cancer; 2012 Apr; 130(7):1695-705. PubMed ID: 21618507
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin.
Syed DN; Adhami VM; Khan MI; Mukhtar H
Anticancer Agents Med Chem; 2013 Sep; 13(7):995-1001. PubMed ID: 23293889
[TBL] [Abstract][Full Text] [Related]
4. The flavonoid fisetin as an anticancer agent targeting the growth signaling pathways.
Rengarajan T; Yaacob NS
Eur J Pharmacol; 2016 Oct; 789():8-16. PubMed ID: 27377217
[TBL] [Abstract][Full Text] [Related]
5. Fisetin inhibits laryngeal carcinoma through regulation of AKT/NF-κB/mTOR and ERK1/2 signaling pathways.
Zhang XJ; Jia SS
Biomed Pharmacother; 2016 Oct; 83():1164-1174. PubMed ID: 27551764
[TBL] [Abstract][Full Text] [Related]
6. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells.
Suh Y; Afaq F; Khan N; Johnson JJ; Khusro FH; Mukhtar H
Carcinogenesis; 2010 Aug; 31(8):1424-33. PubMed ID: 20530556
[TBL] [Abstract][Full Text] [Related]
7. Fisetin, a 3,7,3',4'-Tetrahydroxyflavone Inhibits the PI3K/Akt/mTOR and MAPK Pathways and Ameliorates Psoriasis Pathology in 2D and 3D Organotypic Human Inflammatory Skin Models.
Chamcheu JC; Esnault S; Adhami VM; Noll AL; Banang-Mbeumi S; Roy T; Singh SS; Huang S; Kousoulas KG; Mukhtar H
Cells; 2019 Sep; 8(9):. PubMed ID: 31540162
[TBL] [Abstract][Full Text] [Related]
8. Fisetin regulates obesity by targeting mTORC1 signaling.
Jung CH; Kim H; Ahn J; Jeon TI; Lee DH; Ha TY
J Nutr Biochem; 2013 Aug; 24(8):1547-54. PubMed ID: 23517912
[TBL] [Abstract][Full Text] [Related]
9. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.
Chien CS; Shen KH; Huang JS; Ko SC; Shih YW
Mol Cell Biochem; 2010 Jan; 333(1-2):169-80. PubMed ID: 19633975
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
11. Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma.
Wu R; Hu TC; Rehemtulla A; Fearon ER; Cho KR
Clin Cancer Res; 2011 Dec; 17(23):7359-72. PubMed ID: 21903772
[TBL] [Abstract][Full Text] [Related]
12. Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition.
Tang KD; Ling MT
Curr Med Chem; 2014; 21(26):3048-56. PubMed ID: 24735368
[TBL] [Abstract][Full Text] [Related]
13. Exploring the molecular targets of dietary flavonoid fisetin in cancer.
Syed DN; Adhami VM; Khan N; Khan MI; Mukhtar H
Semin Cancer Biol; 2016 Oct; 40-41():130-140. PubMed ID: 27163728
[TBL] [Abstract][Full Text] [Related]
14. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention.
Tong X; Pelling JC
Anticancer Agents Med Chem; 2013 Sep; 13(7):971-8. PubMed ID: 23272913
[TBL] [Abstract][Full Text] [Related]
15. Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway.
Cai F; Zhang Y; Li J; Huang S; Gao R
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32039440
[TBL] [Abstract][Full Text] [Related]
16. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling.
Syed DN; Chamcheu JC; Khan MI; Sechi M; Lall RK; Adhami VM; Mukhtar H
Biochem Pharmacol; 2014 Jun; 89(3):349-60. PubMed ID: 24675012
[TBL] [Abstract][Full Text] [Related]
17. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
Zou CY; Smith KD; Zhu QS; Liu J; McCutcheon IE; Slopis JM; Meric-Bernstam F; Peng Z; Bornmann WG; Mills GB; Lazar AJ; Pollock RE; Lev D
Mol Cancer Ther; 2009 May; 8(5):1157-68. PubMed ID: 19417153
[TBL] [Abstract][Full Text] [Related]
19. Increase in Anticancer Drug-Induced Toxicity by Fisetin in Lung Adenocarcinoma A549 Spheroid Cells Mediated by the Reduction of Claudin-2 Expression.
Eguchi H; Kimura R; Matsunaga H; Matsunaga T; Yoshino Y; Endo S; Ikari A
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886884
[TBL] [Abstract][Full Text] [Related]
20. Fisetin and Its Role in Chronic Diseases.
Pal HC; Pearlman RL; Afaq F
Adv Exp Med Biol; 2016; 928():213-244. PubMed ID: 27671819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
